Hanlon 1965.

Methods	Randomisation: randomly assigned, no further details. Allocation: procedure not described. Blinding: double ‐ drugs dispensed in standard unmarked pink capsules no. 1 & 0 size, but treating ward physicians were aware of the various drugs and dosages involved in the study. Duration: 30 days. Design: parallel. Location: n.i.. Setting: inpatients.
Participants	Diagnosis: psychotic (270) of which 232 were diagnosed as schizophrenic, 52 neurotics and/or personality disorder. Gender: 160 M, 162 F. Age: mean 36.3 years. History: duration stable ‐ n.i., duration ill ‐ n.i., number of previous hospitalisations ‐ n.i., age at onset ‐ n.i., severity of illness ‐ MSRPP mean 41.4 (15.3), MACC mean 37.5 (10.4), baseline antipsychotic dose ‐ n.i..
Interventions	1. Trifluoperazine: flexible dose, mean dose 11.49 mg/day N = 52. 2. Chlorpromazine: flexible dose, mean dose 395.56 mg/day. N = 52.                  3. Thioridazine: flexible dose, mean dose 193.46 mg/day. N = 53. Rescue medication: antiparkinson medication (biperiden), mild sedation (phenobarbital glutethimide).
Outcomes	Leaving the study early. Adverse events. Unable to use: Mental state: MMPI, MSRPP, IMPS (all incomplete data, no mean, no SD). Behaviour: Behavioral Adjustment Scale (incomplete data). Personality: MMPI (incomplete data). Ward observer measures: (incomplete data).
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomly assigned, no further details.
Allocation concealment (selection bias)	Unclear risk	Procedure not described.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Double ‐ drugs dispensed in standard unmarked pink capsules no. 1 & 0 size, but treating ward physicians were aware of the various drugs and dosages involved in the study.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double ‐ drugs dispensed in standard unmarked pink capsules no. 1 & 0 size, but treating ward physicians were aware of the various drugs and dosages involved in the study. We conclude from this statement that raters were blinded.
Incomplete outcome data (attrition bias) All outcomes	High risk	25% participants from the trifluoperazine group and 21% from the low‐potency group left the study early and were not included in the final analysis (completers only).
Selective reporting (reporting bias)	High risk	MSRPP, MMPI, MACC (no usable data). Not all of the study´s prespecified outcomes have been reported (IMPS and PRP).
Other bias	Unclear risk	Very short duration.